Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

At StockStory, we look beyond the headlines with our independent analysis to determine whether these bearish calls are justified. That said, here is one stock poised to prove Wall Street wrong and two where the skepticism is well-placed.

Two Stocks to Sell:

ON24 (ONTF)

Consensus Price Target: $8.10 (1.6% implied return)

Powering over 1,700 companies' virtual marketing efforts since 1998, ON24 (NYSE: ONTF) provides a cloud-based platform that enables businesses to create interactive digital experiences and capture actionable data from customer engagement.

Why Should You Sell ONTF?

1. Products, pricing, or go-to-market strategy need some adjustments as its billings have averaged 8.1% declines over the last year
2. Sales are expected to decline once again over the next 12 months as it continues working through a challenging demand environment
3. Historical operating margin losses point to an inefficient cost structure

ON24 is trading at $7.98 per share, or 2.5x forward price-to-sales. Check out our free in-depth research report to learn more about why ONTF doesn’t pass our bar.

Zions Bancorporation (ZION)

Consensus Price Target: $65.09 (8.2% implied return)

Founded in 1873 during Utah's pioneer era and named after Mount Zion in the Bible, Zions Bancorporation (NASDAQ: ZION) operates seven regional banks across the Western United States, providing commercial, retail, and wealth management services to over a million customers.

Why Does ZION Fall Short?

1. Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
2. Net interest income is projected to tank by 37.2% over the next 12 months as demand evaporates
3. Earnings per share were flat over the last two years and fell short of the peer group average

Zions Bancorporation’s stock price of $60.15 implies a valuation ratio of 1.3x forward P/B. If you’re considering ZION for your portfolio, see our FREE research report to learn more.

One Stock to Watch:

AbbVie (ABBV)

Consensus Price Target: $245.39 (6% implied return)

Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE: ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, neurological disorders, and other complex health conditions.

Why Are We Fans of ABBV?

1. Unparalleled scale of $59.64 billion in revenue gives it negotiating leverage and staying power in an industry with high barriers to entry
2. Strong free cash flow margin of 36.6% enables it to reinvest or return capital consistently
3. ROIC punches in at 16.7%, illustrating management’s expertise in identifying profitable investments

At $231.56 per share, AbbVie trades at 16.2x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free for active Edge members.

Stocks We Like Even More

If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear.

Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.